Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option

Recruiting now

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

In a certified lung- cancer center, patients with NSCLC and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons. For these patients, the multidisciplinary tumor board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically including PET-CT if indicated. After review of the MDB, patients receive either definitive curative treatment or palliative treatment.

Key facts

Study ID

NCT04926584

Run by

Klinikum Esslingen

People needed

50

Starts

2017-12-15

Expected to finish

2027-12-31

Last updated by the study team

2022-08-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• newly diagnosed NSCLC
• histologically or cytologically proven
• stage III - IVA (oligometastatic) by complete staging
• ECOG 0-2
• life expectancy 3 months
• ability to provide written informed consent

You may not qualify if…

• primary resectability
• primary definitive chemoradiotherapy feasible

Where it is running

• Klinikum Esslingen — Esslingen am Neckar, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.